JAC Advance Access published online on February 6, 2008
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkn020
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commissioned review |
Forgiveness of non-adherence to HIV-1 antiretroviral therapy
Division of Infectious Diseases and AIDS Center, Montefiore Medical Center/Albert Einstein College of Medicine, 111 E 210th Street, Bronx, NY 10467, USA
* Corresponding author. Tel: +1-718-920-7845; Fax: +1-718-405-0610; E-mail: jshuter{at}montefiore.org
Superior adherence to HIV-1 antiretroviral therapy is a mainstay of successful HIV management. Studies performed in the early era of highly active antiretroviral therapy demonstrated the need for
95% adherence in order to achieve and sustain viral suppression. High rates of viral suppression have been observed at more moderate levels of adherence with newer antiretroviral regimens. The term forgiveness is being used to describe the ability of a regimen to achieve and sustain viral suppression, despite suboptimal adherence. A variety of pharmacological, viral and host properties determine the level of forgiveness of any specific regimen. As the choice of treatment options continues to expand, forgiveness of non-adherence is likely to emerge as an increasingly important factor in therapeutic decision-making.
Key Words: AIDS , treatment , compliance , resistance
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. C. Kalichman, H. Pope, D. White, C. Cherry, C. M. Amaral, C. Swetzes, J. Flanagan, and M. O. Kalichman Association Between Health Literacy and HIV Treatment Adherence: Further Evidence from Objectively Measured Medication Adherence J Int Assoc Physicians AIDS Care (Chic Ill), December 1, 2008; 7(6): 317 - 323. [Abstract] [PDF] |
||||
